Thank move operational today. with on everyone. in morning, Financial by Officer. Chris you, Chris be grow Chief to highlights, operator. calling our myself quick we'll here review traditional Prentiss, Excited our remarks from pipeline joining and some And to Connecticut Q&A. closing Today, we'll me and is Danbury, Good financial
the of some quarter about talking by begin me highlights. second Let XXXX
First, record and on DPI royalty Tyvaso revenue we revenue had between coming manufacturing in.
results chronic expected on along Second, way sites to clofazimine inhalation third with enrollment. on our move And suspension is FDA patient as QX for Fast well in of tox. shortly. section the Designation of MAD several as now the way single-dose thirdly, ready anxiously well its by nintedanib well with cohort here Track study is and activated to now with its patients, waiting We're under the DPI
the the here endpoint, our post ADA of received. part We're QX, readout Afrezza. up and We for $XX.X second that XX-week And pediatrics coming plan. ADA data INHALE-X. million, then quarter were half primary third results is moment in in excited well very of pivotal endocrine our implementing data its success at met is endocrine history our and results. and in were these presented second on our revenue expected XX-week shortly. for we're by talk about here I'll had this driven business, to In top INHALE-X line we
delever quarter stock as Mann strong we cash that paying shareholders to GAAP the XX%, sheet, debt $XX by We with non-GAAP to of for convertible net only. loss the company about revenue stock opposed down continue to company the balance of reducing $X talk will record and a up results, million ended the and Chris shortly. $XX with financial in dilution and million, For a million and
as stage clofazimine let [indiscernible] to and with me about and early Now Japan U.S. players X talk had in NTM the years. readout inhalation We over markets great in the data they continue look an the penetrate opportunity at suspension. coming
at see population this Japan. convenient lung with as large of opportunity a look XX%, more bring good we the entrant be well being about the as here market, As that refractory coverage U.S. as this XX% to in a new we could really very
treatment about III days, XX Let disease in for XX a The in. penetration of And me one, talk deep this second is take to will deep believe important days co-pay X lungs product months life, off has drug it's get the treatment. that key it in it What to to the life. and are back because lung the take to about they'll are: the a macrophages long days the for with really half on X We design. our months X the return baseline. Phase off as will the because clofazimine of half for XX this you attributes by have patient followed means
clofazimine month the of looking X primary The months, a and study treatment of will same X off X a that we're coming of in with and X:X see treatment. the dose We X month endpoint milligrams XX thing be and on at randomization.
decide endpoint. larger the first endpoints be staffed or primary trial the XXX after whether that should to enrolled, hit analysis reach interim an have will it's to make our sure we the people sufficiently and will We
is aligned conversion sputum the Japan sputum The co-primary endpoint U.S. in only. for conversion patient been and primary reported and culture outcomes the endpoint is and that has
also to other designation of Japan XX considering and FDA minimum years expanded of have creating QID and IP aligned we're an orphan program. that. have and on We'll given keep posted exclusivity. you single a also along We with us access trial, a
people there of see out you terms from see, and few market, TETON crowded X importantly, United X on are Therapeutics is the this patients. year we as XXX, and it But in while this On options next for very reading excited what is for Tyvaso. on the We're the development, going backbone at longer, to market our of more main drug Ofev, Ofev we thousands focus we an and on opportunity leader believe life that's believe, And it's as people a enhance market quality in brand of it's also live helped and there's phenomenal experience IPF. that when really here. while the of
potentially XX% tolerability of opportunity, how effects, with we effects traditionally alone. the the side GI side GI specifically this to do that because improved occur dropout people at look relative we where bring As Ofev, treatment
an We that higher focus tolerability? into improved hopefully And a we product that can lung this get the our does show directly is little and lungs also GI believe tolerable and really dose here appropriately and this can in we higher concentrations. bit on dose is
move chronic a in then readout to both design I the in The II/III will in a here we FDA XXXX. are data Phase with and meeting to this tox QX, to Phase come expected file in
talk sales some QX, model to of you'll see moving Year-to-date and business predominantly we as $XX.X result as the coming the revenue into $XX.X growth. our over you driven on million. field endocrine of different grew a million, in alone year talk had second. was I prior I'll year, here by business. team Afrezza V-Go XX% Now deprioritized and restructured may a we've about so to Afrezza, about our that that in the QX recall,
Moving into prescriptions.
TRx off what growth, expect to later. It's You X leading months and to QX we into to year. in NRx change NRxs QX X% is can X to quarter-over-quarter. that nice of the see the this to go growth see are growth paying we type The and indicator leading see hope QX, QX that as versus NRx TRx, X% continue to
of sub-analysis presentation an thought X you at The As not on this have this the attributes World readout trial. oral may by read leaders. INHALE-X, was key several or with presented ADA found
target achieved insulin X than of a inhaled AXC versus less participants XX% XX. in one, Number
greater is them. maintain satisfied freedom best to when see XX% and of even and and AID the met such continue Afrezza the XX% people hypoglycemia. they'd said Additionally, to generally trial XX% trial of with than the continue in X no important this number XX% end almost the to got an they'd of coming systems, range like And usual patients Afrezza. we're have treatment switch the that brings to that like technologies reason the versus people to on of X control, that's who increased off Afrezza of were the to XX% in the subjects timing taking Over OmniPod, care with
here the We've the as is our expected QX. the both did XX-week and line, in to look groups, study, people in challenge hours. shows difference this we'll the to learned of our and when a X at improvement later XX-week a dose the initial endpoint, you information meal see end Afrezza, people data primary year of that and the met the the see second at is challenges were relative you to the clearly out on first control you excursions red use shareholders And we can mealtime greater full product. meal can to how give RIA the post-prandial here When in likely glucose right, read to distinct titrated
Afrezza standard over this really can And gives properly of published one us current just the control care. was Care This that hope what dosed ago. post-prandial in last impact significantly of Diabetes couple is data weeks
for the comes adult As groundwork but when inhaled in see transform injected pediatrics, INHALE-X delivery predominant where is choice choosing the it out, to the we look also or population, competitor we alternative as mechanism. laying an pumps to insulin pivotal of
the well the will one trial. be launch. trial in and as show out year and we important will file INHALE-X was for the for consistent showing in in patients, intend to years results that overall as hopefully, The read the And population was as the we'll believe the design subpopulations shortly SWITCH INHALE-X future control next day only MDI really efficacy of that by and in to approval, study in difference INHALE-X
since Afrezza in continued here, gotten grow good year-over-year I've we've really way. When look to we at a
nothing As we year-over-year. the XX, slowing we Afrezza out over XX-plus see years, down, look growing next
now have business. talent to proper this to And Finally, the proper scale have capital data continue readouts, and we label updates. will we
for readouts. wait data will the We
so We for you some can do research, what and readouts are the in plans independent our on what are mean as indication market update to the data we that on additional the conducting shareholders. will as coming with quarters well what
this will But turn grown brand for I and like consistently, we come. to grow Chris. to years now to over to it continue would have we
